Literature DB >> 20456716

Treatment of canine atopic dermatitis: 2010 clinical practice guidelines from the International Task Force on Canine Atopic Dermatitis.

Thierry Olivry1, Douglas J DeBoer, Claude Favrot, Hilary A Jackson, Ralf S Mueller, Tim Nuttall, Pascal Prélaud.   

Abstract

Atopic dermatitis (AD) is a common chronic relapsing pruritic skin disease of dogs for which treatment has varied over time and geographical location. Recent high quality randomized controlled trials and systematic reviews have established which drugs are likely to offer consistent benefit. The International Task Force for Canine AD currently recommends a multi-faceted approach to treat dogs with AD. Acute flares should be treated with a combination of nonirritating baths and topical glucocorticoids, once an attempt has been made to identify and remove the suspected causes of the flare. Oral glucocorticoids and antimicrobial therapy must be added when needed. In dogs with chronic AD, a combination of interventions should be considered. Again, factors that trigger flares of AD must be identified and, if possible, avoided. Currently recognized flare factors include food, flea and environmental allergens, Staphylococcus bacteria and Malassezia yeast. Skin and coat hygiene and care must be improved by bathing with nonirritating shampoos and dietary supplementation with essential fatty acids. The severity of pruritus and skin lesions can be reduced with a combination of anti-inflammatory drugs. Currently, medications with good evidence of high efficacy include topical and oral glucocorticoids, and calcineurin inhibitors such as oral ciclosporin and topical tacrolimus. The dose and frequency of administration of these drugs should be tailored to each patient considering each drug's efficacy, adverse effects and cost. Allergen-specific immunotherapy should be offered, whenever feasible, in an attempt to prevent recurrence of clinical signs upon further exposure to environmental allergens to which the patient is hypersensitive.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20456716     DOI: 10.1111/j.1365-3164.2010.00889.x

Source DB:  PubMed          Journal:  Vet Dermatol        ISSN: 0959-4493            Impact factor:   1.589


  45 in total

1.  Genome-wide linkage study of atopic dermatitis in West Highland White Terriers.

Authors:  Cary A Salzmann; Thierry J M Olivry; Dahlia M Nielsen; Judith S Paps; Tonya L Harris; Natasha J Olby
Journal:  BMC Genet       Date:  2011-04-21       Impact factor: 2.797

2.  Ulcerative dermatitis in C57BL/6 mice exhibits an oxidative stress response consistent with normal wound healing.

Authors:  Lisa K Williams; Lauren S Csaki; Rita M Cantor; Karen Reue; Greg W Lawson
Journal:  Comp Med       Date:  2012-06       Impact factor: 0.982

3.  Evaluation of a DLA-79 allele associated with multiple immune-mediated diseases in dogs.

Authors:  Steven G Friedenberg; Greg Buhrman; Lhoucine Chdid; Natasha J Olby; Thierry Olivry; Julien Guillaumin; Theresa O'Toole; Robert Goggs; Lorna J Kennedy; Robert B Rose; Kathryn M Meurs
Journal:  Immunogenetics       Date:  2015-12-28       Impact factor: 2.846

4.  Current Knowledge on Canine Atopic Dermatitis: Pathogenesis and Treatment.

Authors:  Catherine A Outerbridge; Tyler J M Jordan
Journal:  Adv Small Anim Care       Date:  2021-09-29

Review 5.  An update on the treatment of canine atopic dermatitis.

Authors:  Rosanna Marsella
Journal:  Vet Med (Auckl)       Date:  2012-08-29

6.  Evaluation of the effect of a 0.0584% hydrocortisone aceponate spray on clinical signs and skin barrier function in dogs with atopic dermatitis.

Authors:  Eui-Hwa Nam; Seol-Hee Park; Ji-Young Jung; Seung-Hee Han; Hwa-Young Youn; Jun-Seok Chae; Cheol-Yong Hwang
Journal:  J Vet Sci       Date:  2012-06       Impact factor: 1.672

7.  Spot-on skin lipid complex as an adjunct therapy in dogs with atopic dermatitis: an open pilot study.

Authors:  Masato Fujimura; Yoshinobu Nakatsuji; Subaru Fujiwara; Christophe Rème; Hugues Gatto
Journal:  Vet Med Int       Date:  2011-09-29

8.  The effects of oclacitinib treatment on antimicrobial usage in allergic dogs in primary practice: an Australia wide case-control study.

Authors:  Hester Rynhoud; Catriona Croton; Grace Henry; Erika Meler; Justine S Gibson; Ricardo J Soares Magalhaes
Journal:  BMC Vet Res       Date:  2022-04-27       Impact factor: 2.792

9.  Inhibitory effect of topical adelmidrol on antigen-induced skin wheal and mast cell behavior in a canine model of allergic dermatitis.

Authors:  Santiago Cerrato; Pilar Brazis; Maria Federica Della Valle; Alda Miolo; Anna Puigdemont
Journal:  BMC Vet Res       Date:  2012-11-26       Impact factor: 2.741

10.  A blinded, randomized clinical trial comparing the efficacy and safety of oclacitinib and ciclosporin for the control of atopic dermatitis in client-owned dogs.

Authors:  Peter R Little; Vickie L King; Kylie R Davis; Sallie B Cosgrove; Michael R Stegemann
Journal:  Vet Dermatol       Date:  2014-12-12       Impact factor: 1.589

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.